Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine (“Baylor”), was paused for in-person visits following the guidelines for clinical trials at each institution in March 2020 due to COVID-19. Study visits have now been resumed; several UCLA participants are being examined this week, and Baylor is anticipated to resume its study soon.